News from boehringer ingelheim pharmaceuticals, inc

Jul 02, 2014, 09:00 ET

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim's Investigational Nintedanib and Grants Priority Review Designation for the Treatment of Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been...

Jun 26, 2014, 08:02 ET

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...

Jun 24, 2014, 11:47 ET

Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access...

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

May 30, 2014, 08:00 ET

ASCO 2014: Boehringer Ingelheim to present its latest oncology research including new data for Gilotrif® (afatinib) in advanced lung cancer patients

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif® (afatinib) and investigational compounds,...

May 18, 2014, 17:00 ET

Phase 3 INPULSIS™ Trials Published in the New England Journal of Medicine Show Investigational Nintedanib Slowed Lung Function Loss in People with Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS™ trials (INPULSIS™-1 and -2; NCT01335464 and...

May 15, 2014, 12:45 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed...

May 15, 2014, 08:00 ET

New data for Boehringer Ingelheim's Gilotrif® (afatinib) shows a significant improvement in overall survival in lung cancer patients whose tumors have the most common EGFR mutation

 Boehringer Ingelheim today announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with...

May 14, 2014, 17:46 ET

New data for Boehringer Ingelheim's Gilotrif® (afatinib) shows a significant improvement in overall survival in lung cancer patients whose tumors have the most common EGFR mutation

 Boehringer Ingelheim today announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with...

Apr 30, 2014, 10:15 ET

Boehringer Ingelheim to Present 14 Abstracts at the Annual American Thoracic Society International Conference Including Phase 3 Data on Investigational Therapy Nintedanib

 Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF)...

Apr 17, 2014, 08:00 ET

Volasertib, Boehringer Ingelheim's Investigational Oncology Compound, is Granted Orphan Drug Designation for Acute Myeloid Leukemia in the U.S. and EU

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have...

Apr 14, 2014, 09:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration...

Apr 07, 2014, 08:35 ET

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran...

Mar 28, 2014, 09:00 ET
Nearly 80 Percent of Cardiologists Say Ischemic Stroke Risk Reduction is Their Primary Goal in Non-valvular Atrial Fibrillation Treatment, New Survey Shows.  (PRNewsFoto/Boehringer Ingelheim Pharmaceuticals, Inc.)

Nearly 80 Percent of Cardiologists Say Ischemic Stroke Risk Reduction is Their Primary Goal in Non-valvular Atrial Fibrillation Treatment, New Survey Shows

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions...

Mar 24, 2014, 08:00 ET

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from three company-sponsored PRADAXA studies will be presented at the...

Mar 06, 2014, 07:00 ET

Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir

 Today Boehringer Ingelheim announced results from STARTVerso®4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks...

Mar 05, 2014, 09:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug...

Dec 17, 2013, 08:00 ET

Phase III Study of Dabigatran Etexilate Mesylate Met Primary Endpoint for Six-Month Treatment of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RE-COVER™ II study evaluating dabigatran compared to...

Nov 19, 2013, 08:00 ET

Boehringer Ingelheim Planning to Initiate Two New Global Clinical Trials of Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Pharmaceuticals, Inc. plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI™...

Nov 18, 2013, 12:45 ET

Long-Term Data Presented at American Heart Association Scientific Sessions Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new, long-term, combined analysis of the pivotal Phase III...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer